- Home
- RIGL vs DGICA Comparison
RIGL vs DGICA Comparison
Compare RIGL & DGICA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | DGICA |
|---|---|---|
| Founded | 1996 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.9M | 714.2M |
| IPO Year | 2000 | 1995 |
Fundamental Metrics
Financial Performance| Metric | RIGL | DGICA |
|---|---|---|
| Price | $49.17 | $18.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $63.00 | $21.00 |
| AVG Volume (30 Days) | ★ 194.5K | 94.1K |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 4.15% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | $294,282,000.00 | ★ $978,014,322.00 |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $21.95 | N/A |
| P/E Ratio | $36.91 | ★ $7.82 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $16.11 |
| 52 Week High | $52.24 | $21.06 |
Technical Indicators
Market Signals| Indicator | RIGL | DGICA |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 44.94 |
| Support Level | $33.93 | $17.91 |
| Resistance Level | $49.50 | $19.54 |
| Average True Range (ATR) | 1.86 | 0.36 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 74.01 | 56.19 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.